Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.2 SEK | -1.34% | +13.61% | +24.19% |
04-17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
04-17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.19% | 62.05M | |
+6.52% | 71.18B | |
+11.50% | 9.23B | |
-11.55% | 5B | |
+48.05% | 4.46B | |
+5.09% | 3.95B | |
-14.74% | 2.54B | |
+20.00% | 2.44B | |
-24.89% | 2.36B | |
+21.45% | 2.18B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Orexo's Opioid Use Disorder Drug Study Shows Unexpectedly High Treatment Response Rates